Overview

Study Comparing the Clinical Efficacy and Health Outcomes of Outpatients With Mild to Moderate Community-Acquired Pneumonia (CAP) Treated With Either Telithromycin Once Daily for 7 Days, or Azithromycin Once Daily for 5 Days

Status:
Terminated

Trial end date:
2006-09-01

Target enrollment:

Participant gender:

Summary

A multinational, multicenter, randomized, double-blind, study in areas of high pneumococcal resistance comparing the clinical efficacy and health outcomes of outpatients with mild to moderate Community-Acquired Pneumonia (CAP) treated with either telithromycin once daily for 7 days, or azithromycin once daily for 5 days

Phase:

Phase 4

Details

Lead Sponsor:

Sanofi

Treatments:

Azithromycin
Telithromycin